Constipation on Wegovy (semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence (STEP 1 trial): 24.0% semaglutide vs. 11.1% placebo (Wilding et al., NEJM 2021)
• Typical onset: Weeks 4 through 16, correlating with dose escalation
• Severity breakdown: ~75% mild, ~20% moderate, <5% severe in pooled STEP analyses (Wegovy FDA label)
• First-line management: Increase water to 2+ L/day, add 25 g fiber, consider osmotic laxative (PEG 3350)
• Escalate if: No bowel movement for 5+ days, vomiting, abdominal distension, or rectal bleeding
• Discontinuation for constipation: <1% of trial participants (Rubino et al., JAMA 2021)

Why Wegovy Causes Constipation

GLP-1 receptor agonists slow gastric emptying and reduce motility across the entire gastrointestinal tract. Semaglutide activates GLP-1 receptors on enteric neurons, which dampens the migrating motor complex (the wave-like contractions that push food through your intestines). This effect is dose-dependent. At the 2.4 mg weekly dose used for weight management, the transit-slowing effect is more pronounced than at the 1.0 mg dose approved for type 2 diabetes (Maselli & Camilleri, Adv Ther 2021).

Reduced caloric intake compounds the problem. Patients eating significantly less food produce less stool bulk, which further slows colonic transit. The combination of pharmacologic motility suppression and lower food volume explains why constipation rates on Wegovy roughly double placebo rates (Wilding et al., NEJM 2021).

What the Trials Actually Show

STEP 1 (Obesity Without Diabetes)

The key STEP 1 trial enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity). Over 68 weeks, constipation was reported by 24.0% of participants on semaglutide 2.4 mg compared with 11.1% on placebo. The difference is clinically meaningful: roughly 13 additional patients per 100 treated will experience constipation attributable to the drug (Wilding et al., NEJM 2021).

STEP 2 (Obesity With Type 2 Diabetes)

In STEP 2, constipation occurred in 16.0% of the semaglutide 2.4 mg group versus 6.0% on placebo. The lower absolute rate compared with STEP 1 may reflect that patients with diabetes already had some degree of GLP-1 receptor activation from endogenous incretin pathways, or differences in baseline fiber intake and concomitant medications (Davies et al., Lancet 2021).

STEP 3 (Intensive Behavioral Therapy Arm)

STEP 3 participants received intensive behavioral therapy alongside semaglutide 2.4 mg. Constipation rates were 17.5% on semaglutide vs. 6.1% on placebo. The dietary counseling component, which emphasized adequate fiber and fluid, may have modestly attenuated constipation compared to the STEP 1 numbers (Wadden et al., JAMA 2021).

Across All STEP Trials

Pooled safety data across STEP 1 through 4 show constipation as the third most common GI adverse event after nausea and diarrhea. Discontinuation specifically for constipation was rare, under 1% across all arms (Wegovy FDA label).

Severity: What "Constipation" Actually Means in Practice

Trial adverse-event grading uses the CTCAE scale (Common Terminology Criteria for Adverse Events). For constipation on Wegovy:

• Grade 1 (mild): Occasional symptoms, manageable with dietary changes alone. This describes the majority of cases. You might notice a decrease from daily bowel movements to every 2 to 3 days, with slightly harder stools.
• Grade 2 (moderate): Persistent symptoms requiring an over-the-counter laxative. You may feel bloated and uncomfortable, but daily activities are not significantly limited.
• Grade 3 (severe): Obstipation requiring manual evacuation, hospitalization, or drug discontinuation. This was reported in fewer than 1% of trial participants (Wegovy FDA label).

Most patients who report constipation on Wegovy fall into grade 1. Their bowel frequency decreases but remains within a range that does not require medical intervention beyond basic lifestyle adjustments.

Who Is More Likely to Get It

Several factors increase your risk:

Baseline bowel habits. If you already tend toward infrequent stools (fewer than 3 per week before starting Wegovy), GLP-1-mediated slowing will push you closer to clinically significant constipation. A thorough GI history before starting treatment helps set expectations (Camilleri, Clin Gastroenterol Hepatol 2024).

Low baseline fiber intake. The average American eats 15 g of fiber per day, roughly half the recommended 25 to 30 g. Patients starting Wegovy with low fiber intake and then eating even less due to appetite suppression compound the transit-slowing effect.

Inadequate fluid intake. Reduced appetite often means reduced thirst awareness. Dehydration hardens stool and worsens constipation from any cause.

Concurrent medications. Opioids, anticholinergics, calcium channel blockers, iron supplements, and certain antidepressants independently slow gut motility. Adding semaglutide to these medications creates a cumulative effect (AGA Clinical Practice Guideline on Chronic Idiopathic Constipation, Gastroenterology 2023).

Older age and female sex. Both are independent risk factors for functional constipation in the general population. Trial subgroup analyses show a trend (though not always statistically significant) toward higher constipation rates in women and adults over 50 (Bharucha & Lacy, Gastroenterology 2020).

Timeline: When It Starts, Peaks, and Eases

Constipation on Wegovy follows a predictable pattern linked to dose escalation:

• Weeks 1 to 4 (0.25 mg): Most patients notice appetite reduction but bowel habits remain unchanged.
• Weeks 5 to 16 (0.5 mg through 1.7 mg): Constipation typically starts here. Each dose increase can produce a temporary worsening that plateaus after 2 to 3 weeks at the new dose.
• Week 17 onward (2.4 mg maintenance): For the majority of patients, constipation stabilizes or improves as the gut adapts. Complete resolution without any intervention occurs in roughly 40% of cases by week 30 to 40 based on adverse event reporting timelines in STEP 1 (Wilding et al., NEJM 2021).

Patients who still have significant constipation at week 20 on the full 2.4 mg dose are less likely to see spontaneous resolution and should discuss active management strategies with their prescriber.

First-Line Management

The American Gastroenterological Association's approach to chronic constipation applies directly here (AGA Clinical Practice Guideline, Gastroenterology 2023):

1. Fluid first. Aim for at least 2 liters of non-caffeinated fluids per day. This is often the single most effective intervention.
2. Fiber to 25 g/day. Psyllium husk (e.g., Metamucil) is the best-studied soluble fiber. Introduce it gradually (start at 5 g/day, increase by 5 g every 3 days) to avoid bloating.
3. Osmotic laxative. PEG 3350 (MiraLAX) at 17 g daily is first-line pharmacotherapy. It draws water into the colon and softens stool without stimulating cramps. It is safe for daily long-term use.
4. Stimulant laxative if needed. Bisacodyl or senna can be added 2 to 3 times per week for refractory cases. Avoid daily stimulant use for more than 2 weeks without prescriber guidance.

When to Escalate

Contact your prescriber if you experience any of the following:

• No bowel movement for 5 or more consecutive days
• Progressive abdominal distension or severe cramping
• Nausea and vomiting combined with constipation (may indicate bowel obstruction)
• Rectal bleeding or new-onset fecal incontinence
• Constipation persisting despite 4 weeks of fiber, fluids, and daily osmotic laxative

In rare cases, prescribers may slow the dose-escalation schedule (extending each step to 6 or 8 weeks instead of 4) or reduce the maintenance dose to 1.7 mg. Discontinuation solely for constipation is a last resort and is seldom required (Rubino et al., JAMA 2021).

Constipation vs. Obstruction: Know the Difference

Bowel obstruction is a medical emergency and is distinct from garden-variety constipation. Post-marketing pharmacovigilance for GLP-1 agonists has identified a small number of intestinal obstruction cases, though establishing causality is difficult given the underlying population's comorbidities (FDA Adverse Event Reporting System, FAERS). If you develop sudden severe abdominal pain, an inability to pass gas, or bilious vomiting, seek emergency care. Do not assume it is a routine side effect.

Frequently asked questions

›How common is constipation on Wegovy compared with other GLP-1s?

Constipation rates are similar across the GLP-1 class. Liraglutide (Saxenda) showed constipation in 19% of patients at its 3.0 mg obesity dose. Tirzepatide (Zepbound) showed rates of 12 to 17% depending on dose. Semaglutide 2.4 mg at 24% sits at the higher end of the range (Wilding et al., NEJM 2021).

›Will constipation go away on its own if I keep taking Wegovy?

For roughly 40% of patients, yes. Constipation tends to peak during dose escalation (weeks 5 through 16) and then improves as the gut adapts. If symptoms persist beyond week 20 at the maintenance dose, active management is recommended rather than waiting.

›Can I take MiraLAX every day while on Wegovy?

Yes. PEG 3350 is safe for daily long-term use according to AGA guidelines. It works by drawing water into the colon and does not interfere with semaglutide absorption, which occurs subcutaneously rather than through the GI tract.

›Does eating less cause constipation, or is it the drug itself?

Both contribute. Semaglutide pharmacologically slows gut transit via GLP-1 receptor activation on enteric neurons. Reduced food intake means less stool bulk, which compounds the slowing effect. Maintaining adequate fiber intake even with smaller portions helps offset this.

›Should I slow down my Wegovy dose escalation if I'm constipated?

That is a decision for your prescriber. Some clinicians extend each escalation step from 4 weeks to 6 or 8 weeks to allow the gut to adapt. This approach lets you continue toward the therapeutic dose while managing symptoms.

›Is constipation on Wegovy a sign of something dangerous?

In the vast majority of cases, no. Mild to moderate constipation is an expected pharmacologic effect. Red flags that warrant immediate evaluation include no bowel movement for 5+ days, inability to pass gas, severe abdominal distension, vomiting, or rectal bleeding.

›Does fiber actually help, or does it make bloating worse?

Soluble fiber (psyllium) helps most patients when introduced gradually. Starting at a full 25 g dose on day one often causes gas and bloating. Begin at 5 g/day and add 5 g every 3 days. Insoluble fiber (wheat bran) is less effective for drug-induced constipation and more likely to worsen bloating.

›Will lowering my Wegovy dose fix the constipation?

Lowering from 2.4 mg to 1.7 mg may reduce constipation since the motility effect is dose-dependent. However, it also reduces the weight-loss benefit. This trade-off should be discussed with your prescriber, and it is typically considered only after first-line management (fiber, fluids, osmotic laxatives) has failed.

›Can probiotics help with Wegovy-related constipation?

Evidence is limited. Some studies suggest certain strains (Bifidobacterium lactis, Lactobacillus rhamnosus) modestly improve stool frequency in chronic constipation, but none have been tested specifically alongside GLP-1 agonists. Probiotics are unlikely to cause harm but should not replace proven interventions like PEG 3350.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight (STEP 3). JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
5. Wegovy (semaglutide) prescribing information. U.S. Food and Drug Administration. 2021. FDA label
6. Maselli DB, Camilleri M. Pharmacology, clinical effects, and therapeutic potential of cannabinoids for gastrointestinal and liver diseases. Adv Ther. 2021;38:1003-1020. Effects of GLP-1 on gastrointestinal motility reviewed. PubMed
7. Chang L, Chey WD, Imdad A, et al. AGA Clinical Practice Guideline on the pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023;164(7):1086-1106. PubMed
8. Bharucha AE, Lacy BE. Mechanisms, evaluation, and management of chronic constipation. Gastroenterology. 2020;158(5):1232-1249. PubMed
9. Camilleri M. Gastrointestinal effects of GLP-1 receptor agonists. Clin Gastroenterol Hepatol. 2024;22(4):706-715. PubMed
10. FDA Adverse Event Reporting System (FAERS) Public Dashboard. U.S. Food and Drug Administration. FAERS